LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Home・Aktien・Amicus Therapeutics Inc

Amicus Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

9.48 1.07

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

9.26

Max

9.55

Schlüsselkennzahlen
By Trading Economics
Einkommen	-2.7M -24M
Verkäufe	29M 155M
Gewinnspanne	-15.787
Angestellte	499
EBITDA	-1M -5.8M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+68.58% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	461M 2.3B
Vorheriger Eröffnungskurs	8.41
Vorheriger Schlusskurs	9.48

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

5.925 / 7.38 Unterstützung & Widerstand

Amicus Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Nov. 2025, 17:45 UTC

Ergebnisse

Wichtige Markttreiber

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14. Nov. 2025, 17:31 UTC

Ergebnisse

Wichtige Markttreiber

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

14. Nov. 2025, 16:15 UTC

Wichtige Markttreiber

Scholar Rock Shares Rise on Renewed Apitegromab Hopes

14. Nov. 2025, 23:56 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14. Nov. 2025, 23:02 UTC

Market Talk

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14. Nov. 2025, 22:35 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14. Nov. 2025, 22:32 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14. Nov. 2025, 22:29 UTC

Ergebnisse

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14. Nov. 2025, 22:00 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14. Nov. 2025, 21:50 UTC

Market Talk

Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

14. Nov. 2025, 21:18 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14. Nov. 2025, 20:27 UTC

Market Talk

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14. Nov. 2025, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14. Nov. 2025, 20:17 UTC

Akquisitionen, Fusionen, Übernahmen

Several State Attorneys General Oppose Railroad Merger -- WSJ

14. Nov. 2025, 19:29 UTC

Market Talk

Ergebnisse

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14. Nov. 2025, 18:44 UTC

Market Talk

Ergebnisse

Disney's Growth Now Hinges More on ESPN -- Market Talk

14. Nov. 2025, 18:27 UTC

Market Talk

Global Equities Roundup: Market Talk

14. Nov. 2025, 18:27 UTC

Market Talk

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14. Nov. 2025, 18:20 UTC

Market Talk

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14. Nov. 2025, 17:20 UTC

Market Talk

Ergebnisse

Auto & Transport Roundup: Market Talk

14. Nov. 2025, 17:20 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Health Care Roundup: Market Talk

14. Nov. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14. Nov. 2025, 16:51 UTC

Market Talk

Starbucks Gets Holiday Sales Lift -- Market Talk

14. Nov. 2025, 16:48 UTC

Market Talk

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

14. Nov. 2025, 16:38 UTC

Market Talk

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

14. Nov. 2025, 16:30 UTC

Akquisitionen, Fusionen, Übernahmen

Merck Is Paying Up for Flu Biotech as M&A Spree Continues -- Barrons.com

14. Nov. 2025, 16:28 UTC

Market Talk

Ukraine Strike on Russian Port Lifts Distillates -- Market Talk

14. Nov. 2025, 15:59 UTC

Market Talk

U.S. Natural Gas Inventories Rise More Than Expected -- Market Talk

14. Nov. 2025, 15:06 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14. Nov. 2025, 15:06 UTC

Market Talk

Dollar Could Benefit From U.K., French Fiscal Concerns -- Market Talk

Peer-Vergleich

Kursveränderung

Amicus Therapeutics Inc Prognose

Kursziel

By TipRanks

68.58% Vorteil

12-Monats-Prognose

Durchschnitt 15.88 USD 68.58%

Hoch 21 USD

Tief 11 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Amicus Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

8 ratings

Buy

Halten

Sell

Basierend auf 8 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Amicus Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

5.925 / 7.38Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.